Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-O maintenance strategy in newly diagnosed advanced ovarian cancer
CTR20210499Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, bevacizumab, olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Started May 2021; status: terminated.
02
Drugs
durvalumabbevacizumabolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20210499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210499.